ZANATTA, ELISABETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.479
AS - Asia 2.002
EU - Europa 1.566
SA - Sud America 565
AF - Africa 525
OC - Oceania 66
Continente sconosciuto - Info sul continente non disponibili 22
Totale 8.225
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.165
SG - Singapore 626
IT - Italia 425
BR - Brasile 372
HK - Hong Kong 336
CN - Cina 326
DE - Germania 180
FI - Finlandia 103
VN - Vietnam 94
NL - Olanda 78
PL - Polonia 70
FR - Francia 60
RU - Federazione Russa 60
IN - India 58
GB - Regno Unito 54
SE - Svezia 49
AT - Austria 40
KR - Corea 35
JP - Giappone 33
CO - Colombia 31
TR - Turchia 31
EC - Ecuador 30
MX - Messico 28
AR - Argentina 27
ES - Italia 26
IQ - Iraq 25
BG - Bulgaria 24
DO - Repubblica Dominicana 24
IE - Irlanda 24
KH - Cambogia 24
AZ - Azerbaigian 23
AE - Emirati Arabi Uniti 22
AM - Armenia 22
GR - Grecia 22
LU - Lussemburgo 22
SO - Somalia 22
UZ - Uzbekistan 22
CA - Canada 21
IR - Iran 21
ME - Montenegro 21
PY - Paraguay 21
UA - Ucraina 20
BE - Belgio 19
GT - Guatemala 19
IL - Israele 19
JM - Giamaica 19
MK - Macedonia 19
PA - Panama 19
SA - Arabia Saudita 19
AL - Albania 18
BS - Bahamas 18
CZ - Repubblica Ceca 18
GA - Gabon 18
NI - Nicaragua 18
SN - Senegal 18
TN - Tunisia 18
UG - Uganda 18
AU - Australia 17
JO - Giordania 17
LB - Libano 17
RO - Romania 17
RW - Ruanda 17
ZA - Sudafrica 17
ID - Indonesia 16
KE - Kenya 16
MY - Malesia 16
TT - Trinidad e Tobago 16
TZ - Tanzania 16
UY - Uruguay 16
BW - Botswana 15
CM - Camerun 15
CV - Capo Verde 15
DK - Danimarca 15
HU - Ungheria 15
KG - Kirghizistan 15
MG - Madagascar 15
ML - Mali 15
NO - Norvegia 15
PS - Palestinian Territory 15
SK - Slovacchia (Repubblica Slovacca) 15
ZW - Zimbabwe 15
AO - Angola 14
BA - Bosnia-Erzegovina 14
BD - Bangladesh 14
BO - Bolivia 14
GF - Guiana Francese 14
HT - Haiti 14
MA - Marocco 14
MR - Mauritania 14
MW - Malawi 14
SI - Slovenia 14
VE - Venezuela 14
XK - ???statistics.table.value.countryCode.XK??? 14
BF - Burkina Faso 13
CH - Svizzera 13
LC - Santa Lucia 13
LY - Libia 13
NC - Nuova Caledonia 13
NZ - Nuova Zelanda 13
PE - Perù 13
Totale 7.631
Salva come PNG Salva come JPEG
Città #
Singapore 435
Ashburn 406
Fairfield 405
Hong Kong 325
Chandler 281
Woodbridge 175
Cambridge 139
Houston 138
Seattle 124
Santa Clara 121
Ann Arbor 105
Beijing 105
Wilmington 101
Boardman 96
Munich 93
Padova 81
Los Angeles 68
San Diego 58
Chicago 55
Hefei 51
Helsinki 48
Bytom 47
Ho Chi Minh City 38
Milan 37
Medford 35
Princeton 35
São Paulo 35
Buffalo 32
Turku 28
Des Moines 26
New York 25
Baku 22
Phnom Penh 22
Hanoi 21
Seoul 21
Yerevan 21
Nuremberg 20
Rio de Janeiro 20
Tashkent 20
Salt Lake City 19
Vienna 19
Athens 18
Kampala 18
Managua 18
Sofia 18
Amman 17
Dakar 17
Dublin 17
Stockholm 17
Libreville 16
Montevideo 16
Nassau 16
Panama City 16
Podgorica 16
Rome 16
Bishkek 15
Kigali 15
Luxembourg 15
Nairobi 15
Naples 15
Antananarivo 14
Bengaluru 14
Lappeenranta 14
London 14
Brooklyn 13
Castries 13
Dili 13
Dushanbe 13
Elk Grove Village 13
Falkenstein 13
Harare 13
Hargeisa 13
Istanbul 13
Kingston 13
Nouakchott 13
Phoenix 13
Praia 13
Tokyo 13
Bamako 12
Dar es Salaam 12
Johannesburg 12
Noumea 12
San José 12
Warsaw 12
Baghdad 11
Cayenne 11
Dallas 11
Ljubljana 11
Ogden 11
Tampa 11
Tel Aviv 11
Abidjan 10
Amsterdam 10
Bologna 10
Luanda 10
Minsk 10
Nanjing 10
Papeete 10
Pristina 10
Reykjavik 10
Totale 4.741
Salva come PNG Salva come JPEG
Nome #
Therapy of scleroderma renal crisis: State of the art 191
SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients 187
Evaluation of right ventricular function performed by 3d-echocardiography in scleroderma patients 185
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study 177
Mud-bath treatment of seronegative spondyloarthritis: experience at the Euganean Thermal Area 174
Anti-MDA5 dermatomyositis: an update from bench to bedside 169
IL-12 and IL-23/Th17 axis in systemic lupus erythematosus 166
Balneotherapy in chronic inflammatory rheumatic diseases—a narrative review 162
Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies 161
MicroRNAs in idiopathic inflammatory myopathies: state-of-the-art and future perspectives 160
Clinical outcomes and predictors of maternal and fetal complications in pregnancies of patients with systemic lupus erythematosus 159
Nailfold avascular score and coronary microvascular dysfunction in systemic sclerosis: A newsworthy association 156
Squamous cell carcinoma antigen-IgM (SCCA-IgM) is associated with interstitial lung disease in systemic sclerosis 151
Correction to: Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies. 149
Belimumab: a step forward in the treatment of systemic lupus erythematosus 149
The power of the EUSTAR cohort: key findings to date and implicationsfor management of systemic sclerosis patients 145
Pulmonary arterial hypertension in connective tissue disorders: Pathophysiology and treatment 142
Interstitial lung disease with and without progressive fibrosing phenotype in patients with idiopathic inflammatory myopathies: data from a large multicentric cohort 141
How I treat patients with systemic sclerosis in clinical practice 137
Cocaine- and Levamisole-Induced Vasculitis: Defining the Spectrum of Autoimmune Manifestations 136
Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry 'SPRING' of the Italian Society for Rheumatology 135
PD-1 gene rs2227981 (PD-1.5) polymorphism analysis in patients with systemic sclerosis 132
Low occurrence of digital ulcers in scleroderma patients treated with bosentan for pulmonary arterial hypertension: a retrospective case-control study. 127
The interferon in idiopathic inflammatory myopathies: Different signatures and new therapeutic perspectives. A literature review 123
Inflammation and coronary microvascular dysfunction in autoimmune rheumatic diseases 120
Skin ulcers in systemic sclerosis: correlation with clinical phenotype in a monocentric cohort from the north-east of Italy 120
Long-term improvement in activities of daily living in women with systemic sclerosis attending to occupational therapy. 119
Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis 113
Circulating extracellular vesicles and small non-coding RNAs cargo in idiopathic inflammatory myopathies reveal differences across myositis subsets 112
Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management 112
Alcoholic Etiology, Severity of Liver Disease, and Post-Transplant Adherence Are Correlated with Worse Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) in Liver Transplant Candidates 103
New onset and flare of rheumatic diseases following COVID-19 vaccination are mild and respond well to treatment: 9-month follow-up data from a single centre cohort 100
Effects of mud-bath applications on synovial inflammation evaluated by contrasted-enhanced ultrasound (CEUS) in patients with psoriatic arthritis 99
Covid-19 and rheumatic autoimmune systemic diseases: Role of pre-existing lung involvement and ongoing treatments 97
NITRIC OXIDE DIFFUSION IN PATIENTS WITH SSc 96
Pseudotumoral calcinosis in systemic sclerosis: Data from systematic literature review and case series from two referral centres 95
Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review 95
Size-Exclusion Chromatography Combined with Ultrafiltration Efficiently Isolates Extracellular Vesicles from Human Blood Samples in Health and Disease 94
Systemic sclerosis Progression INvestiGation (SPRING) Italian registry: demographic and clinico-serological features of scleroderma spectrum 94
Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database 94
Urinary incontinence in systemic sclerosis: a prospective multicentre cohort study 92
Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database 91
Prevalence of diaphragm dysfunction in patients with interstitial lung disease (ILD): The role of diaphragmatic ultrasound 90
CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies 89
The PREdictor of MAlnutrition in Systemic Sclerosis (PREMASS) Score: A Combined Index to Predict 12 Months Onset of Malnutrition in Systemic Sclerosis 88
Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study 88
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study—Joint and Skin (BeRLiSS-JS) 86
Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from EUSTAR cohort 86
Higher Ventricular-Arterial Coupling Derived from Three-Dimensional Echocardiography Is Associated with a Worse Clinical Outcome in Systemic Sclerosis 85
Coronary microvascular dysfunction in autoimmune rheumatic diseases: beyond coronary flow velocity reserve 84
Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies 83
Systemic sclerosis sine scleroderma in children 82
Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology 82
Autoantibodies Targeting G-Protein-Coupled Receptors: Pathogenetic, Clinical and Therapeutic Implications in Systemic Sclerosis 81
Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort 80
Update on Rheumatic Diseases in Clinical Practice 79
Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research 79
Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time? 76
Geographical heterogeneity of clinical and serological phenotypes of systemic sclerosis observed at tertiary referral centres. The experience of the Italian SIR-SPRING registry and review of the world literature 75
Evaluation of extracellular vesicles as potential biomarkers of myositis 74
Should we use nintedanib as early therapy in patients with SSc-ILD? 72
The role of plasma exchange in the management of autoimmune disorders 70
Serum Biomarkers in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension 69
Systemic sclerosis: Recent insight in clinical management 69
Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study 68
Capillary Desertification and Refractory Digital Ulcers in Systemic Sclerosis 68
Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual 66
Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition 66
Hypovitaminosis D in an hospitalized old population of Western Friuli 64
Systemic sclerosis sine scleroderma is more aggressive in children than in adults 60
Prevalence and death rate of COVID-19 in systemic autoimmune diseases in the first three pandemic waves. Relationship to disease subgroups and ongoing therapies 57
The Challenge of Diagnosing and Managing Pulmonary Arterial Hypertension in Systemic Sclerosis with Interstitial Lung Disease 57
Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Viewer or Actor? To Treat or Not to Treat? 55
Improvement with time of vascular outcomes in systemic sclerosis: a systematic review and meta-analysis study 54
Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort 51
Systemic sclerosis: state of the art on clinical practice guidelines 45
The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort 42
Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review 41
The Influence of Dietary Intervention in Connective Tissue Diseases: Evidence from Randomized Clinical Trials 40
Cardiovascular involvement as a clue for diagnosis of Juvenile Systemic Sclerosis sine scleroderma 40
Scleroderma renal crisis: Case reports and update on critical issues 39
Late Skin Fibrosis in Systemic Sclerosis: A Study from the EUSTAR Cohort 39
Primordial and primary prevention in rheumatological diseases: The time has come 32
Does body composition matter in patients with systemic sclerosis? 21
Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort 15
Glucocorticoids prescribing practices in systemic sclerosis: an analysis of the EUSTAR database 10
Late skin fibrosis in systemic sclerosis: a study from the EUSTAR cohort 9
Totale 8.366
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.543
article - articoli 30.959
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 62.502
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021513 0 0 0 44 17 22 12 48 59 29 43 239
2021/2022504 14 35 50 29 13 70 40 41 25 40 37 110
2022/2023556 88 55 18 82 78 72 7 35 65 19 20 17
2023/2024568 21 57 66 51 50 64 42 27 35 30 57 68
2024/20252.219 30 170 89 118 213 95 185 183 126 101 383 526
2025/20263.318 506 659 1.160 993 0 0 0 0 0 0 0 0
Totale 8.366